Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?

Background Triple-negative breast cancer (TNBC) is associated with aggressive tumor behavior and worse outcomes. In a study at a tertiary care breast unit in a developing country, clinico-pathological attributes and outcomes of patients with TNBC were compared with (c.w.) ER, PR, and/or HER2 express...

Full description

Saved in:
Bibliographic Details
Published in:World journal of surgery 2016-06, Vol.40 (6), p.1362-1372
Main Authors: Agarwal, Gaurav, Nanda, Gitika, Lal, Punita, Mishra, Anjali, Agarwal, Amit, Agrawal, Vinita, Krishnani, Narendra
Format: Article
Language:English
Subjects:
Abdominal Surgery
Adult
Age Factors
Aged
Biomarkers, Tumor - metabolism
Breast Cancer
Breast Cancer Patient
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Cardiac Surgery
Cohort Studies
Combined Modality Therapy
Female
General Surgery
Humans
Infiltrate Ductal Carcinoma
Kaplan-Meier Estimate
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Grading
Neoplasm Staging
Original Scientific Report
Overall Survival
Prognosis
Receptor, ErbB-2 - metabolism
Receptors, Estrogen - metabolism
Receptors, Progesterone - metabolism
Retrospective Studies
Surgery
Thoracic Surgery
TNBC Patient
Treatment Outcome
Triple Negative Breast Neoplasms - metabolism
Triple Negative Breast Neoplasms - pathology
Triple Negative Breast Neoplasms - therapy
Vascular Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Triple-negative breast cancer (TNBC) is associated with aggressive tumor behavior and worse outcomes. In a study at a tertiary care breast unit in a developing country, clinico-pathological attributes and outcomes of patients with TNBC were compared with (c.w.) ER, PR, and/or HER2 expressing tumors (non-TNBC). Patients and methods Medical records of 1213 consecutive breast cancer patients managed during 2004–2010 were reviewed. An evaluable cohort of 705 patients with complete treatment and follow-up (median 36 months) information was thus identified. Patients were categorized per ER, PR & HER2 status into TNBC, and ER/PR+ and/or HER2+ groups. Clinico-pathological parameters, response to NACT, and OS & DFS were compared between TNBC and non-TNBC groups. Results TNBC patients ( n  = 249) comprised 35.3 % of the study cohort ( n  = 705), and were significantly younger than non-TNBC patients (mean age 49.1 ± 11.2y c.w. 51.8 ± 11.3, p  = 0.02). The TNM stage at presentation was similar in the two groups (Stage I and II—37 % c.w. 44.3 %, Stage III—47.5 % c.w. 39.5 %, Stage IV—15.5 % c.w. 16.2 % in TNBC c.w. Non-TNBC; p  = 0.09). Tumor size (5.7 ± 2.9 cm TNBC c.w. 5.4 ± 2.8 cm non-TNBC, p  = 0.22) was similar but lymph nodal (cN) metastases were more frequent in TNBC (77.3 % c.w. 69.8 %; p  = 0.03). TNBC had higher histologic grade (97.1 % gr II/III in TNBC c.w. 91.2 % non-TNBC, p  = 0.01) and higher incidence of LVI (20.4 % in TNBC c.w. 13.5 %, p  = 0.03). Patient groups received similar multi-disciplinary surgical, radiation, and systemic treatment. Comparable proportion of patients in 2 groups were treated with NACT (42 % c.w. 38 %), which resulted in pathological complete response (pCR) in 27.5 % TNBC patients c.w. 17.1 % non-TNBC patients ( p  = 0.04). Both OS (81.8 ± 4.52 c.w. 97.90 ± 3.87 months, p  
ISSN:0364-2313
1432-2323
DOI:10.1007/s00268-016-3422-4